article thumbnail

Medical Device Innovation: Transforming The Workplace

MedCity News

Medical device companies that leverage today’s technology to better share and track product and safety information will outpace rivals and gain a competitive edge. They will be the innovators that can solve problems faster and streamline their workflows for optimal efficiency.

Medical 284
article thumbnail

Structure Raises $300M as Oral GLP-1 Drug’s Data Keep Up With Pfizer, Eli Lilly

MedCity News

Preliminary weight loss and safety data for Structure Therapeutics’ drug candidate suggest it’s competitive with other oral GLP-1 targeting contenders from big pharma companies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Incyte's Opzelura clears skin in children with atopic dermatitis, but safety remains a question

Fierce Pharma

Fighting for a place in the competitive atopic dermatitis market, Incyte hopes to reach younger patients with its JAK inhibitor cream Opzelura. Fighting for a place in the competitive atopic dermatitis market, Incyte hopes to reach young patients with its JAK inhibitor cream Opzelura.

Safety 180
article thumbnail

With phase 3 miss, Pfizer's DMD candidate is no threat to Sarepta's Elevidys ahead of key label expansion: analysts

Fierce Pharma

With a phase 3 miss following a fatality in a related study and marking what analysts are calling the “final nail” in Pfizer’s Duchenne muscular dystrophy (DMD) gene therapy coffin, Sarepta Therape | With a phase 3 miss and severe safety signals, Pfizer's Duchenne muscular dystrophy gene therapy candidate is no competition to Sarepta's established (..)

article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. Tentative approval means Lumryz has satisfied all the FDA requirements for efficacy, safety, and quality standards, but it can’t be fully approved until a patent or other exclusivity expires. Competition starts to heat up. Classic treatment options. Two decades of exclusivity.

article thumbnail

Promising schizophrenia drug faces tough competition

European Pharmaceutical Review

Thus, LY03010 could be more convenient to administer and improve patient compliance by optimising the initial dosing regimen, while ensuring efficacy and safety. The post Promising schizophrenia drug faces tough competition appeared first on European Pharmaceutical Review.

article thumbnail

AbelsonTaylor Group Receives the Healthcare Businesswomen’s Association ACE Aspire Award for its Employee Psychological Safety Initiative

PM360

Award-winning health and wellness advertising agency AbelsonTaylor Group received the inaugural ACE Aspire Award for its employee Psychological Safety Initiative from the Healthcare Businesswomen’s Association (HBA). In 2022, AbelsonTaylor developed and implemented a large-scale, ongoing Psychological Safety initiative for its 300 employees.

Safety 111